- Home
- SRFM vs CTSO Comparison
SRFM vs CTSO Comparison
Compare SRFM & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRFM
- CTSO
- Stock Information
- Founded
- SRFM 2011
- CTSO 1997
- Country
- SRFM United States
- CTSO United States
- Employees
- SRFM N/A
- CTSO N/A
- Industry
- SRFM Transportation Services
- CTSO Medical/Dental Instruments
- Sector
- SRFM Consumer Discretionary
- CTSO Health Care
- Exchange
- SRFM Nasdaq
- CTSO Nasdaq
- Market Cap
- SRFM 58.2M
- CTSO 52.6M
- IPO Year
- SRFM 2023
- CTSO N/A
- Fundamental
- Price
- SRFM $3.95
- CTSO $1.03
- Analyst Decision
- SRFM Buy
- CTSO Buy
- Analyst Count
- SRFM 4
- CTSO 2
- Target Price
- SRFM $5.56
- CTSO $5.50
- AVG Volume (30 Days)
- SRFM 13.7M
- CTSO 134.9K
- Earning Date
- SRFM 08-13-2025
- CTSO 08-12-2025
- Dividend Yield
- SRFM N/A
- CTSO N/A
- EPS Growth
- SRFM N/A
- CTSO N/A
- EPS
- SRFM N/A
- CTSO N/A
- Revenue
- SRFM $112,307,000.00
- CTSO $35,332,238.00
- Revenue This Year
- SRFM N/A
- CTSO $18.34
- Revenue Next Year
- SRFM $54.32
- CTSO $19.82
- P/E Ratio
- SRFM N/A
- CTSO N/A
- Revenue Growth
- SRFM 31.17
- CTSO 15.37
- 52 Week Low
- SRFM $0.90
- CTSO $0.71
- 52 Week High
- SRFM $6.72
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- SRFM 64.64
- CTSO 49.00
- Support Level
- SRFM $3.30
- CTSO $0.93
- Resistance Level
- SRFM $4.16
- CTSO $1.39
- Average True Range (ATR)
- SRFM 0.79
- CTSO 0.13
- MACD
- SRFM 0.17
- CTSO -0.02
- Stochastic Oscillator
- SRFM 61.32
- CTSO 34.92
About SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.